European Cystinosis Cohort 2
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Long-term clinical disease progression in cystinosis
研究概览
简要总结
This European observational cohort follows patients with cystinosis, a rare lysosomal storage disease caused by CTNS mutations leading to cystine accumulation and multisystem involvement. It aims to describe the long-term clinical course under current treatments, focusing on renal and extra-renal complications, survival, and quality of life. It also evaluates treatment effects and explores biomarkers, including inflammatory markers, with biobanking for future research.
详细描述
Cystinosis is a rare autosomal recessive lysosomal storage disorder caused by pathogenic variants in the CTNS gene encoding cystinosin, the lysosomal cystine transporter. The resulting defect leads to progressive intralysosomal cystine accumulation, causing multisystem cellular dysfunction and progressive organ involvement. The disease typically presents in infancy with renal Fanconi syndrome and progresses to chronic kidney disease and, without cystine-depleting therapy, end-stage kidney disease in childhood. With advances in cysteamine therapy, renal replacement therapy, and kidney transplantation, survival has improved significantly, resulting in a chronic multisystem disease affecting both pediatric and adult populations.
At the cellular level, cystinosis involves lysosomal dysfunction, impaired autophagy, oxidative stress, dysregulated endolysosomal trafficking, and chronic inflammatory activation. Macrophage activation and inflammatory pathways are increasingly recognized as contributors to disease progression.
This study is conducted within the RaDiCo-ECYSCO platform, a European rare disease cohort designed for standardized longitudinal data collection in patients with cystinosis followed in expert reference centers. ECYSCO2 is the continuation of the original ECYSCO cohort and extends long-term follow-up and harmonized clinico-biological data collection.
The cohort is multicentric and includes specialized centers across Europe. It is embedded in routine clinical care, and data collection is non-interventional and based on standard follow-up procedures without modification of patient management.
Data are collected using standardized electronic case report forms (eCRFs) within the REDCap® platform of the RaDiCo information system. The system supports full data lifecycle management including data capture, validation, monitoring, and statistical analysis. Source data are defined as medical records, laboratory reports, imaging data, and patient questionnaires (paper or electronic). Investigators are responsible for ensuring consistency between source documents and eCRF entries.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of cystinosis based on leukocyte cystine measurement, presence of corneal cystine crystals, and/or molecular genetic diagnosis
- •Signed informed consent obtained from the patient or legal representative
排除标准
- •Patients unable to provide informed consent or without a legal representative when required
- •No other specific exclusion criteria; patients with associated diseases may be included
结局指标
主要结局
Long-term clinical disease progression in cystinosis
时间窗: Through study completion, an average of 6 years
Evaluation of long-term disease progression in patients with cystinosis, including renal function (eGFR, renal replacement therapy), ocular involvement, endocrine manifestations, neurological abnormalities, muscular and gastrointestinal complications, and survival. Additional data include current treatments and CTNS genotyping.
次要结局
- Quality of life in patients with cystinosis (adults)(Through study completion, an average of 6 years)
- Quality of life in patients with cystinosis (children)(Through study completion, an average of 6 years)
- Treatment adherence in patients with cystinosis(Through study completion, an average of 6 years)
- Renal function assessment in patients with cystinosis(Through study completion, an average of 6 years)
- Ocular manifestations assessment in patients with cystinosis(Through study completion, an average of 6 years)
- Endocrine manifestations assessment in patients with cystinosis(Through study completion, an average of 6 years)
- Neurological, gastrointestinal, muscular and dermatological manifestations assessment in patients with cystinosis(Through study completion, an average of 6 years)
- Cystinosis treatment exposure(Through study completion, an average of 6 years)
- Long-term safety and adverse events of treatments(Through study completion, an average of 6 years)
- Biological sample collection and biomarker analysis(Baseline and every 2 years during follow-up, and at disease events)
